Results 21 to 30 of about 44,264 (223)

Amiodarone pneumonitis

Journal of the Belgian Society of Radiology, 2010
Background: A 65-year-old male patient presented with progressive shortness of breath over the past 3 months, recently even at rest. He neither complained about fever nor about chest pain. The laboratory findings were normal with only a slight increase in leucocytes. A significant restrictive ventilation disorder was noted on plethysmography.
Bley, T A, François, C J
openaire   +5 more sources

Effect of heart rate control with amiodarone infusion on hemodynamic and clinical outcomes in septic shock patients with tachycardia: a prospective, single-arm clinical study

Journal of Pharmaceutical Health Care and Sciences, 2021
Background Keeping the heart rate within the normal range has improved the survival of septic shock patients. Amiodarone could target the underlying pathophysiology of sepsis-induced tachycardia.
Masoud Khataminia, Farhad Najmeddin, Atabak Najafi, Hamidreza Sharifnia, Arezoo Ahmadi, Adeleh Sahebnasagh, Mojtaba Mojtahedzadeh   +6 more
doaj   +1 more source

Amiodarone Use and All‐Cause Mortality in Patients With a Continuous‐Flow Left Ventricular Assist Device

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Atrial and ventricular arrhythmias are commonly encountered in patients with advanced heart failure, with amiodarone being the most commonly used antiarrhythmic drug in continuous‐flow left ventricular assist device (CF‐LVAD) recipients.
Rakesh Gopinathannair, Naga Venkata K. Pothineni, Jaimin R. Trivedi, Henri Roukoz, Jennifer Cowger, Mustafa M. Ahmed, Adarsh Bhan, Ashwin K. Ravichandran, Geetha Bhat, Amin Al Ahmad, Andrea Natale, Luigi Di Biase, Mark S. Slaughter, Dhanunjaya Lakkireddy   +13 more
doaj   +1 more source

Amiodarone-induced reversible and irreversible hepatotoxicity: two case reports

Journal of Medical Case Reports, 2018
Background Amiodarone is a highly effective treatment for supraventricular and ventricular tachyarrhythmia; however, it could be associated with several serious adverse effects, including liver injury.
Toyonobu Tsuda, Hayato Tada, Yoshihiro Tanaka, Naoto Nishida, Taiji Yoshida, Takeshi Sawada, Kenji Sakata, Kenshi Hayashi, Masa-aki Kawashiri, Takeru Oyama, Motoko Sasaki, Nozomu Kurose, Masakazu Yamagishi   +12 more
doaj   +1 more source

Cardiomyocyte-Targeting Peptide to Deliver Amiodarone

Pharmaceutics, 2023
Background: Amiodarone is underutilized due to significant off-target toxicities. We hypothesized that targeted delivery to the heart would lead to the lowering of the dose by utilizing a cardiomyocyte-targeting peptide (CTP), a cell-penetrating peptide ...
Maliha Zahid, Beth Weber, Ray Yurko, Kazi Islam, Vaishavi Agrawal, Jack Lopuszynski, Hisato Yagi, Guy Salama   +7 more
doaj   +1 more source

Management of amiodarone-related thyroid problems

Therapeutic Advances in Endocrinology and Metabolism, 2011
Amiodarone is a highly effective and well-established antiarrrhythmic drug. It can be used to treat supraventricular and ventricular tachyarrhythmias and has the added advantage of being well tolerated in patients with impaired left ventricular systolic ...
Shashithej K. Narayana, David R. Woods, Christopher J. Boos   +2 more
doaj   +1 more source

Systematic review of the use of intravenous amiodarone and nifekalant for cardiopulmonary resuscitation in Japan

Journal of Arrhythmia, 2014
Background: Intravenous amiodarone is considered to be the first-line drug for the treatment of ventricular tachycardia or fibrillation. However, in Japan, nifekalant had been used before the introduction of amiodarone; therefore, most clinical studies ...
Mari Amino, MD, PhD, Koichiro Yoshioka, MD, PhD, Shigetaka Kanda, MD, Yoshiaki Deguchi, MD, PhD, Mari Nakamura, MD, Yoshinori Kobayashi, MD, PhD, Sadaki Inokuchi, MD, PhD, Teruhisa Tanabe, MD, PhD, Yuji Ikari, MD, PhD   +8 more
doaj   +1 more source

Amiodarone-Induced Acute Liver Injury

Case Reports in Gastroenterology, 2020
Amiodarone is a lipophilic structure with a half-life of 25–100 days. Long-term oral amiodarone is associated with photosensitivity, thyroid dysfunction, and pulmonary and hepatic toxicity.
Rajesh Essrani, Shehriyar Mehershahi, Rajesh Kumar Essrani, Shri Jai Kirshan Ravi, Sajeer Bhura, Anuraj Sudhakaran, Muhammad Hossain, Asif Mehmood   +7 more
doaj   +1 more source

NF-κB inhibitor or NAC attenuates amiodarone-induced injury of human lung epithelial cell line BEAS-2B [PDF]

Jichu yixue yu linchuang
Objective To investigate the mechanism of reactive oxygen species (ROS) and pyroptosis in amiodarone-induced lung epithelial cell injury. Methods The viability of cells treated with amiodarone, amiodarone+N-acetylcysteine(ROS inhibitor,NAC) and ...
JI Zezhao, ZHANG Qi, Abuduxukuer·ABULIMITI
doaj   +1 more source

Intravenous Amiodarone

Journal of the American College of Cardiology, 1997
Intravenous amiodarone was approved in 1995 for the treatment of malignant and resistant ventricular arrhythmia. Although it is an "old drug," much has been learned recently about this complex drug and its application in a variety of cardiac arrhythmias.
Kowey, Peter R, Marinchak, Roger A, Rials, Seth J, Filart, Roland A   +3 more
openaire   +2 more sources